#ESMO19 – Randomized Trial: Improved Overall Survival with a CDK4/6 Inhibitor for Hormone Receptor-positive, ERBB2-negative Advanced Breast Cancer
30 Sep, 2019 | 00:40h | UTCCommentary: Two Studies Show CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer [ESMO 2019 Press Release] (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona